Consensus recommendations from the American Acne & Rosacea Society on the Management of Rosacea, Part 3: A status report on systemic therapies

Cutis

Volumn 93, Issue 1, 2014, Pages 18-28

  Del Rosso, James Q ^a,b   Thiboutot, Diane ^c   Gallo, Richard ^d   Webster, Guy ^e   Tanghetti, Emil ^f   Eichenfield, Lawrence F ^g,h   Stein Gold, Linda ⁱ   Berson, Diane ^j   Zaenglein, Andrea ^c  

^a TOURO UNIVERSITY NEVADA   (United States)

^b Las Vegas Skin and Cancer Clinics   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

^f Center for Dermatology and Laser Surgery   (United States)

^g RADY CHILDREN'S HOSPITAL   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ HENRY FORD HOSPITAL   (United States)

^j NEW YORK PRESBYTERIAN HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DERMATOLOGICAL AGENT;

ARTICLE; CONSENSUS; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDICAL SOCIETY; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; ROSACEA; UNITED STATES;

ADMINISTRATION, ORAL; CONSENSUS; DERMATOLOGIC AGENTS; DRUG APPROVAL; HUMANS; ROSACEA; SOCIETIES, MEDICAL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84893175012     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (92)

1. Del Rosso JQ, Thiboutot D, Gallo RL, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 1: a status report on the disease state, general measures, and adjunctive skin care. Cutis. 2013;92:234-240.
2. Steinhoff M, Buddenkotte J, Aubert J, et al. Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. J Invest Dermatol Symp Proc. 2011;15:2-11.
3. McAleer MA, Lacey N, Powell FC. The pathophysiology of rosacea. G Ital Dermatol Venereol. 2009;144:663-671.
4. Del Rosso JQ, Gallo RL, Tanghetti E, et al. An evaluation of potential correlations between pathophysiologic mechanisms, clinical manifestations, and management of rosacea. Cutis. 2013;91(suppl 3):1-8.
5. Yamasaki K, Gallo RL. The molecular pathology of rosacea [published online ahead of print May 29, 2009]. J Dermatol Sci. 2009;55:77-81.
6. Fleischer AB Jr. Inflammation in rosacea and acne: implications for patient care. J Drugs Dermatol. 2011;10:614-620.
7. Yamasaki K, Gallo RL. Rosacea as a disease of cathelicidins and skin innate immunity. J Investig Dermatol Symp Proc. 2011;15:12-15.
8. Del Rosso JQ. Advances in understanding and managing rosacea: part 1: connecting the dots between pathophysiological mechanisms and common clinical features of rosacea with emphasis on vascular changes and facial erythema. J Clin Aesthet Dermatol. 2012;5:16-25.
9. Del Rosso JQ. Advances in understanding and managing rosacea: part 2: the central role, evaluation, and management of diffuse and persistent facial erythema of rosacea. J Clin Aesthet Dermatol. 2012;5:26-36.
10. Crawford GH, Pelle MT, James WD. Rosacea: I. etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004;51:327-341; quiz 342-344.
11. Helfrich YR, Varani J, Fisher GJ, et al. Mast cell and neuropeptide expression are increased in erythematotelangiectatic rosacea in comparison to telangiectatic photoaging. Poster presented at: Society of Investigative Dermatology Annual Meeting; May 9-12, 2012; Raleigh, NC. P093.
12. Lazaridou E, Giannopoulou C, Fotiadou C, et al. The potential role of microorganisms in the development of rosacea [in English, German][published November 8, 2010]. J Dtsch Dermatol Ges. 2011;9:21-25.
13. Pelle MT, Crawford GH, James WD. Rosacea: II. therapy. J Am Acad Dermatol. 2004;51:499-512; quiz 513-514.
14. Del Rosso JQ. Medical treatment of rosacea with emphasis on topical therapies. Expert Opin Pharmacother. 2004;5:5-13.
15. Del Rosso JQ, Baum EW. Comprehensive medical management of rosacea: an interim study report and literature review. J Clin Aesthet Dermatol. 2008;1:20-25.
16. Odom R, Dahl M, Dover J, et al. Standard management options for rosacea, part 2: options according to rosacea subtype. Cutis. 2009;84:97-104.
17. Kennedy Carney C, Cantrell W, Elewski BE. Rosacea: a review of current topical, systemic and light-based therapies. G Ital Dermatol Venereol. 2009;144:673-688.
18. van Zuuren EJ, Kramer S, Carter B, et al. Interventions for rosacea [published online ahead of print March 16, 2011]. Cochrane Database Syst Rev. 2011:CD003262.
19. Del Rosso JQ. Anti-inflammatory dose doxycycline in the treatment of rosacea. J Drugs Dermatol. 2009;8:664-668.
20. Bikowski JB. Subantimicrobial dose doxycycline for acne and rosacea. Skinmed. 2003;2:234-245.
21. Del Rosso JQ, Webster GW, Jackson M, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea [published online ahead of print March 23, 2007]. J Am Acad Dermatol. 2007;56:791-802.
22. Fowler JF Jr. Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea. J Drugs Dermatol. 2007;6:641-645.
23. Oracea [package insert]. Fort Worth, TX: Galderma Laboratories LP; 2013.
24. Preshaw PM, Novak MJ, Mellonig J, et al. Modified-release subantimicrobial dose doxycycline enhances scaling and root planing in subjects with periodontal disease. J Periodontol. 2008;79:440-452.
25. Modi S, Harting M, Rosen T. Azithromycin as an alternative rosacea therapy when tetracyclines prove problematic. J Drugs Dermatol. 2008;7:898-899.
26. Park H, Del Rosso JQ. Use of oral isotretinoin in the management of rosacea. J Clin Aesthet Dermatol. 2011;4:54-61.
27. Korting HC, Schöllmann C. Tetracycline actions relevant to rosacea treatment [published online ahead of print September 25, 2009]. Skin Pharmacol Physiol. 2009;22:287-294.
28. Quarterman MJ, Johnson DW, Abele DC, et al. Ocular rosacea. signs, symptoms, and tear studies before and after treatment with doxycycline. Arch Dermatol. 1997;133:49-54.
29. Pfeffer I, Borelli C, Zierhut M, et al. Treatment of ocular rosacea with 40 mg doxycycline in a slow release form [in English, German][published online ahead of print June 15, 2011]. J Dtsch Dermatol Ges. 2011;9:904-907.
30. Bakar O, Demircay Z, Toker E, et al. Ocular signs, symptoms and tear function tests of papulopustular rosacea patients receiving azithromycin [published online ahead of print February 24, 2009]. J Eur Acad Dermatol Venereol. 2009;23:544-549.
31. Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006;54:258-265.
32. Webster G, Del Rosso JQ. Anti-inflammatory activity of tetracyclines. Dermatol Clin. 2007;25:122-135, v.
33. Golub LM, Lee HM, Ryan ME, et al. Tetracyclines inhibit connective tissue breakdown by multiple nonantimicrobial mechanisms. Adv Derm Res. 1998;12:12-26.
34. Del Rosso JQ. Update on rosacea pathogenesis and correlation with medical therapeutic agents. Cutis. 2006;78:97-100.
35. Del Rosso JQ, Bruce S, Jarratt M, et al. Efficacy of topical azelaic acid (AzA) gel 15% plus oral doxycycline 40 mg versus metronidazole gel 1% plus oral doxycycline 40 mg in mild-to-moderate papulopustular rosacea. J Drugs Dermatol. 2010;9:607-613.
36. Webster GF. An open-label, community-based, 12-week assessment of the effectiveness and safety of monotherapy with doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads). Cutis. 2010;86(suppl 5):7-15.
37. Del Rosso JQ. Effectiveness and safety of doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads) once daily as add-on therapy to existing topical regimens for the treatment of papulopustular rosacea: results from a community-based trial. Cutis. 2010;86(suppl 5):16-25.
38. Del Rosso JQ, Schlessinger J, Werschler P. Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. J Drugs Dermatol. 2008;7:573-576.
39. Thiboutot DM, Fleischer AB, Del Rosso JQ, et al. A multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance monotherapy. J Drugs Dermatol. 2009;8:639-648.
40. Fleischer A, Suephy C. The face and mind evaluation study: an examination of the efficacy of rosacea treatment using physician ratings and patients' self-reported quality of life. J Drugs Dermatol. 2005;4:585-590.
41. Jackson JM, Kircik LH, Lorenz DJ. Efficacy of extended-release 45 mg oral minocycline and extended-release 45 mg oral minocycline plus 15% azelaic acid in the treatment of acne rosacea. J Drugs Dermatol. 2013;12:292-298.
42. Del Rosso JQ, Baldwin H, Webster G; American Acne & Rosacea Society. American Acne & Rosacea Society rosacea medical management guidelines. J Drugs Dermatol. 2008;7:531-533.
43. Cribier B. Pathophysiology of rosacea: redness, telangiectasia, and rosacea. Ann Dermatol Venereol. 2011;138(suppl 3):S184-S191.
44. Yamasaki K, Kanada K, Macleod DT, et al. TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes [published online ahead of print November 25, 2010]. J Invest Dermatol. 2011;131:688-697.
45. Meyer-Hoffert U, Schröder JM. Epidermal proteases in the pathogenesis of rosacea. J Investig Dermatol Symp Proc. 2011;15:16-23.
46. Gerber PA, Buhren BA, Steinhoff M, et al. Rosacea: the cytokine and chemokine network. J Investig Dermatol Symp Proc. 2011;15:40-47.
47. Schwab VD, Sulk M, Seeliger S, et al. Neurovascular and neuroimmune aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc. 2011;15:53-62.
48. Sulk M, Seeliger S, Aubert J, et al. Distribution and expression of non-neuronal transient receptor potential (TRPV) ion channels in rosacea [published online ahead of print December 22, 2011]. J Invest Dermatol. 2012;132:1253-1262.
49. Del Rosso JQ, Gallo RL, Kircik L, et al. Why is rosacea considered to be an inflammatory disorder? the primary role, clinical relevance, and therapeutic correlations of abnormal innate immune response in rosacea-prone skin. J Drugs Dermatol. 2012;11:694-700.
50. Kanada KN, Nakatsuji T, Gallo RL. Doxycycline indirectly inhibits proteolytic activation of tryptic kallikrein-related peptidases and activation of cathelicidin [published online ahead of print February 16, 2012]. J Invest Dermatol. 2012;132:1435-1442.
51. McKeage K, Deeks ED. Doxycycline 40 mg capsules (30 mg immediate-release/10 mg delayed-release beads): anti-inflammatory dose in rosacea. Am J Clin Dermatol. 2010;11:217-222.
52. Thiboutot D. Efficacy and safety of subantimicrobial-dose doxycycline for the treatment of rosacea. Poster presented at: 63rd Annual Meeting of the American Academy of Dermatology; February 18-22, 2005; New Orleans, LA. P128.
53. Sanchez J, Somolinos AL, Almodóvar PI, et al. A randomized, double-blind, placebo-controlled trial of the combined effect of doxycycline hyclate 20-mg tablets and metronidazole 0.75% topical lotion in the treatment of rosacea [published online ahead of print September 15, 2005]. J Am Acad Dermatol. 2005;53:791-797.
54. Theobald K, Bradshaw M, Leyden J. Anti-inflammatory dose doxycycline (40 mg controlled-release) confers maximum anti-inflammatory efficacy in rosacea. Skinmed. 2007;6:221-226.
55. Thomas J, Walker C, Bradshaw M. Long-term use of subantimicrobial dose doxycycline does not lead to changes in antimicrobial susceptibility. J Periodontol. 2000;71:1472-1483.
56. Skidmore R, Kovach R, Walker C, et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol. 2003;139:459-464.
57. Golub LM, Sorsa T, Lee HM, et al. Doxycycline inhibits neutrophil (PMN)-type matrix metalloproteinases in human adult periodontitis gingiva. J Clin Periodontol. 1995;22:100-109.
58. Golub LM, Ramamurthy NS, McNamara TF, et al. Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Crit Rev Oral Biol Med. 1991;2:297-321.
59. Hanemaaijer R, Visser H, Koolwijk P, et al. Inhibition of MMP synthesis by doxycycline and chemically modified tetracyclines (CMTs) in human endothelial cells. Adv Dent Res. 1998;12:114-118.
60. Webster GF, Toso SM, Hegemann L. Inhibition of a model of in vitro granuloma formation by tetracyclines and ciprofloxacin. involvement of protein kinase C. Arch Dermatol. 1994;130:748-752.
61. Amin AR, Attur MG, Thakker GD, et al. A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci USA. 1996;93:14014-14019.
62. Valentín S, Morales A, Sánchez JL, et al. Safety and efficacy of doxycycline in the treatment of rosacea. Clin Cosmet Investig Dermatol. 2009;2:129-140.
63. Bhatia ND, Del Rosso JQ. Optimal management of papulopustular rosacea: rationale for combination therapy. J Drugs Dermatol. 2012;11:838-44.
64. Kim S, Michaels BD, Kim GK, et al. Systemic antibacterial agents. In: Wolverton SE, ed. Comprehensive Dermatologic Therapy. 3rd ed. Philadelphia, PA: Elsevier Saunders; 2013:61-97.
65. Del Rosso JQ. Patterns of use of topical and oral therapies in the treatment of different subtypes of rosacea. Presented at: 11th Annual South Beach Symposium; April 11-15, 2013; Miami Beach, Florida.
66. Leyden JJ, Del Rosso JQ. Oral antibiotic therapy for acne vulgaris: pharmacokinetic and pharmacodynamic perspectives. J Clin Aesthet Dermatol. 2011;4:40-47.
67. Smilack JD. The tetracyclines. Mayo Clin Proc. 1999;74:727-729.
68. Stockley IH. Antibiotics and anti-infective agents. In: Stockley IH, eds. Drug Interactions. 5th ed. London, England: Pharmaceutical Press; 1999:196-197.
69. Leyden JJ. Absorption of minocycline hydrochloride and tetracycline hydrochloride. effect of food, milk, and iron. J Am Acad Dermatol. 1985;12(2, pt 1):308-312.
70. Layton AM, Cunliffe WJ. Phototoxic eruptions due to doxycycline-a dose-related phenomenon. Clin Exp Dermatol. 1993;18:425-427.
71. Smith K, Leyden JJ. Safety of doxycycline and minocycline: a systematic review. Clin Ther. 2005;27:1329-1342.
72. Sloan B, Scheinfeld N. The use and safety of doxycycline hyclate and other second-generation tetracyclines. Expert Opin Drug Saf. 2008;7:571-577.
73. Del Rosso JQ. Systemic therapy for rosacea: focus on oral antibiotic therapy and safety. Cutis. 2000;66(suppl 4):7-13.
74. Truchuelo-Díez MT, Alcántara J, Carrillo R, et al. Demodicosis successfully treated with repeated doses of oral ivermectin and permethrin cream. Eur J Dermatol. 2011;21:777-778.
75. Forstinger C, Kittler H, Binder M. Treatment of rosacea-like demodicosis with oral ivermectin and topical permethrin cream. J Am Acad Dermatol. 1999;41(5, pt 1):775-777.
76. Pierog SH, Al-Salihi FL, Cinotti D. Pseudotumor cerebri-a complication of tetracycline treatment of acne. J Adolesc Health Care. 1986;7:139-140.
77. Berger RS. A double-blind, multiple-dose, placebo-controlled, cross-over study to compare the incidence of gastrointestinal complaints in healthy subjects given Doryx R and Vibramycin R. J Clin Pharmacol. 1988;28:367-370.
78. Akhyani M, Ehsani AH, Ghiasi M, et al. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of rosacea: a randomized open clinical trial. Int J Dermatol. 2008;47:284-288.
79. Bakar O, Demirçay Z, Gürbüz O. Therapeutic potential of azithromycin in rosacea. Int J Dermatol. 2004;43:151-154.
80. Fernandez-Obregon A. Oral use of azithromycin for the treatment of acne rosacea. Arch Dermatol. 2004;140:489-490.
81. Torresani C, Pavesi A, Manara GC. Clarithromycin versus doxycycline in the treatment of rosacea. Int J Dermatol. 1997;36:942-946.
82. Tamaoki J, Kadota J, Takizawa H. Clinical implications of the immunomodulatory effects of macrolides. Am J Med. 2004;117(suppl 9A):5S-11S.
83. Amsden GW. Anti-inflammatory effects of macrolides-an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions [published online ahead of print December 8, 2004]? J Antimicrob Chemother. 2005;55:10-21.
84. Bakar O, Demirçay Z, Yuksel M, et al. The effect of azithromycin on reactive oxygen species in rosacea [published online ahead of print January 18, 2007]. Clin Exp Dermatol. 2007;32(2):197-200.
85. Coda AB, Hata T, Miller J, et al. Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel [published online ahead of print July 18, 2013]. J Am Acad Dermatol. 2013;69:570-577.
86. Leyden JJ, Del Rosso JQ, Webster GF. Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: focus on antibiotic resistance. Cutis. 2007;79(suppl 6):9-25.
87. Gollnick H, Blume-Peytavi U, Szabó EL, et al. Systemic isotretinoin in the treatment of rosacea-doxycycline-and placebo-controlled, randomized clinical study [in English, German][published online ahead of print March 12, 2010]. J Dtsch Dermatol Ges. 2010;8:505-515.
88. Hofer T. Continuous 'microdose' isotretinoin in adult recalcitrant rosacea. Clin Exp Dermatol. 2004;29:204-205.
89. Pinheiro SP, Kang EM, Kim CY, et al. Concomitant use of isotretinoin and contraceptives before and after iPLEDGE in the United States [published online ahead of print August 3, 2013]. Pharmacoepidemiol Drug Saf. 2013;22:1251-1257.
90. Jansen T, Plewig G. Clinical and histologic variants of rosacea, including nonsurgical treatment modalities. Facial Plast Surg. 1998;14:241-253.
91. Solodyn [package insert]. Scottsdale, AZ: Medicis, a Division of Valeant Pharmaceuticals; 2011.
92. Doryx [package insert]. Rockaway, NJ: Warner Chilcott, LLC; 2013.